BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
76.80
-0.56 (-0.72%)
At close: Nov 17, 2026, 4:00 PM EST
76.76
-0.04 (-0.05%)
After-hours: Nov 17, 2026, 5:52 PM EST

BridgeBio Pharma Stock Forecast

Stock Price Forecast

According to 22 analysts polled by S&P Global, BridgeBio Pharma stock has a consensus rating of "Buy" and an average price target of $107. The average 1-year stock price forecast is 39.32% higher than the current stock price, while the lowest is $80 (+4.17%) and the highest is $156 (+103.13%).

Price Target: $107 (+39.32%)
Analyst Consensus: Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$80$107$107.5$156
Change+4.17%+39.32%+39.97%+103.13%

Analyst Ratings

The average analyst rating for BridgeBio Pharma stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Chart
RatingJun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Strong Buy161414141414
Buy665555
Hold223333
Sell000000
Strong Sell000000
Total242222222222

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Morgan Stanley
Morgan Stanley
Buy
Maintains
$88 → $91
BuyMaintains$88 → $91+18.49%Nov 13, 2026
Canaccord Genuity
Canaccord Genuity
Buy
Maintains
$106 → $108
BuyMaintains$106 → $108+40.63%Nov 2, 2026
Barclays
Barclays
Buy
Maintains
$156
BuyMaintains$156+103.13%Nov 2, 2026
Bank of America Securities
Bank of America Securities
Buy
Maintains
n/a
BuyMaintainsn/an/aOct 30, 2026
RBC Capital
RBC Capital
Buy
Maintains
$100
BuyMaintains$100+30.21%Oct 30, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
1.10B
from 502.08M
Increased by 118.56%
Revenue Next Year
1.66B
from 1.10B
Increased by 51.71%
EPS This Year
-2.45
from -3.78
EPS Next Year
-0.27
from -2.45
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
69.72M77.65M9.30M221.90M502.08M1.10B
Revenue Growth
745.15%11.38%-88.02%2,285.27%126.26%118.56%
Gross Profit
66.60M74.21M6.86M218.02M481.11M1.03B
Gross Margin
95.53%95.58%73.71%98.25%95.82%93.71%
Operating Income
-573.33M-468.44M-599.44M-577.37M-502.06M-311.87M
Net Income
-562.54M-481.18M-643.20M-535.76M-724.93M-515.64M
EPS
-----3.78-2.45
Free Cash Flow
-----447.01M-257.56M
No. Analysts
-----17
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High1.1B
Avg1.1B
Low1.1B

Revenue Growth

Revenue Growth202620272028
High
122.2%
Avg
118.6%
Low
113.1%

EPS Forecast

EPS202620272028
High-2.09
Avg-2.45
Low-2.81

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-